<DOC>
	<DOCNO>NCT02530320</DOCNO>
	<brief_summary>This multicenter , open-label , phase II trial aim ass safety efficacy palbociclib adult patient Oligodendroglioma recurrent oligoastrocytoma anaplastic activity protein RB preserve .</brief_summary>
	<brief_title>Safety Efficacy PD0332991 ( Palbociclib ) , Cyclin-dependent Kinase 4 6 Inhibitor , Patients With Oligodendroglioma Recurrent Oligoastrocytoma Anaplastic With Activity Protein RB Preserved</brief_title>
	<detailed_description />
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>1 . Ability understand sign inform consent approve Ethic Committee . 2 . Men woman age great equal 18 . 3 . Patients oligodendroglioma anaplastic oligoastrocytoma anaplastic accord WHO classification histologically confirm . Note : It include patient oligoastrocytoma oligodendroglioma G2 suffer recurrence diagnosis resection G3 . 4 . Patients relapse radiotherapy one two line chemotherapy . Note : Both previous radiotherapy chemotherapy could receive adjuvant therapy previous recurrence . It also accept received concurrent chemoradiotherapy . In secondary oligodendrogliomas oligoastrocytomas anaplastic , patient could receive chemotherapy radiotherapy tumor G2 . 5 . All patient present positivity immunohistochemical study RB protein tumor sample send central lab . 6 . The case must 10 slide tumor block available biopsy surgery . 7 . All patient show disease progression cerebral nuclear magnetic resonance . 8 . Interval least one week previous intracranial biopsy inclusion . 9 . Interval least 12 week radiotherapy inclusion , unless : ) Recurrent tumor confirm histologically b ) recurrency show NMR radiotherapy . 10 . Patients recover previous therapy : 28 day since end investigational product since end cytotoxic treatment . 11 . ECOG≤2 12 . Stable decrease dose corticoid five day prior inclusion 13. patient suffer tumor resection last recurrence eligible : A good surgery recover measurable evaluable disease surgery 14 . Good bone marrow function : Neutrophils ≥ 1500/mm3 ( 1.5x10e9/L ) Platelet ≥ 100.000/mm3 ( 100 x 10e9 ) Hemoglobin ≥ 9 g/dL Seric creatinine ≤ 1.5 x LSN site estimate clearance ≥ 60 ml/min calculate . Bilirubin ≤ 1.5 x LSN ( Gilbert 's syndrome ≤ 3 xLSN ) AST ( SGOT ) and/or ALT ≤ 3 x LSN ; alkaline phosphatase ≤ 2.5 x LSN . 15 . Nor pregnant woman breastfeed woman . Women heterosexual activity negative pregnant test inclusion study . Both woman men use accept contraceptive method study treatment 1 month treatment complete . 1 . Presence meningeal carcinomatosis disseminate . 2 . Concomitant treatment investigational product 3 . Previous treatment wih investigational product could active CDK4/6 4 . Any kind surgery previous 2 week 5 . Presence clinically significant gastrointestinal abnormality affect oral administration , transit absorption study drug , inability take medication mouth tablet . 6 . Presence psychiatric cognitive disorder limit understanding signature inform consent / jeopardize fulfillment requirement protocol . 7 . In 7 day prior begin treatment , receive treatment : Drugs inhibitor CYP3A4 Drugs inductor CYP3A4 Drugs extend QT interval 8 . QTc interval &gt; 480 msec , familiar history personal QT large Syndrome , QT short Syndrome , Brugada syndrome , QTc extension Torsade de Pointes history 9 . Electrolyte disorder may affect QTc interval 10 . Significant uncontrolled cardiovascular disease , include : Myocardial infarction within previous 12 month Uncontrolled angina within previous 6 month Congestive heart failure previous 6 month History clinically significant ventricular arrhythmia type ( ventricular tachycardia , ventricular fibrillation torsades de pointes ) History second third grade heart block ( patient may eligible currently pacemaker ) Ictus Pulmonary embolism 11 . History cancer , except follow circumstance : Patients history malignancy eligible free disease least last 3 year , discretion investigator , low risk disease recurrence . Patients follow cancer eligible even diagnose treat last 3 year : carcinoma situ cervix basal cell basal cell skin carcinoma . Patients ineligible evidence neoplastic disease require therapy surgery past 3 year . 12 . Patients positive HIV 13 . Inflammatory bowel disease , chronic diarrhea , short gut syndrome upper gastrointestinal surgery include gastric resection . 14 . History allergic reaction Palbociclib 15 . Another acute chronic serious medical condition , uncontrolled intercurrent illness laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation test result , investigator 's discretion , make patient inappropriate entry trial . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness / social situation limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Palbociclib</keyword>
	<keyword>oligodendroglioma</keyword>
	<keyword>oligoastrocytoma anaplastic</keyword>
</DOC>